- Vaccine stocks Moderna and Novavax continue to decline, dropping over 30% in the last month
- Trump’s nomination of Robert F. Kennedy Jr. to head HHS fuels concerns over his vaccine stance
- RFK Jr.’s vocal criticism of vaccines adds uncertainty to the future of pharma stocks
It’s been a tough week for vaccine stocks. Moderna is down, Novavax is down, and even Pfizer has fallen. What’s the catalyst for this?
It was an announcement by President-elect Donald Trump that Robert F. Kennedy Jr. will head the Department of Health and Human Services. News that sent the pharma world into a stir—at least from the investors’ perspective.
What’s Behind the Drop?
What’s behind the slump? Well, it’s no secret that Kennedy harbors hard-nosed anti-vaccine views. Upon confirmation of Kennedy’s appointment by Trump, stocks for Moderna and Novavax tanked over 30% in the last month.
Investors are concerned that the views held by Kennedy might mean new regulatory hurdles for these companies.
Trump’s Audacious Move
Trump doubled down with Kennedy, seemingly promising, “I’m going to let him go wild on healthcare.”
Kennedy’s been a vocal opponent of vaccines through his nonprofit. This week, he created waves with this statement: “There’s no vaccine that is safe and effective.”
A Quick Tejano, Then What?
With the announcement, stocks plummeted, and it seems the downfall might further deteriorate. The question now lingers: will Kennedy’s influence reshape the vaccine market? It is not altogether clear, but the uncertainty itself is enough to create some serious unease.
What Does This Mean for the Future of Pharma Stocks?
The immediate prospects for vaccine stocks are poor. Under Kennedy’s appointment at HHS, Moderna and Novavax could be in for a more difficult time.
Skittish is the mood in the market, and the pharma sector—let alone its vaccine stocks—can hardly take all this uncertainty.
